Literature DB >> 24052605

Video-assisted thoracoscopic lobectomy in non-small-cell lung cancer patients with chronic obstructive pulmonary disease is associated with lower pulmonary complications than open lobectomy: a propensity score-matched analysis.

Jae Hyun Jeon1, Chang Hyun Kang, Hye-Seon Kim, Yong Won Seong, In Kyu Park, Young Tae Kim, Joo Hyun Kim.   

Abstract

OBJECTIVES: Non-small-cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of pulmonary complications after pulmonary resection. This study aimed to identify whether video-assisted thoracoscopic (VATS) lobectomy can reduce postoperative pulmonary complications compared with lobectomy by thoracotomy in NSCLC patients with COPD.
METHODS: Among a total of 1502 NSCLC patients who underwent lobectomy from April 2005 to June 2012 at the Seoul National University Hospital, 446 (29.7%) were diagnosed with COPD based on the spirometric criteria of the Global Initiative for COPD. Among the 446 patients, 283 presented with stage I NSCLC and were selected for this study. The study patients were divided into two groups: patients undergoing VATS (n = 160) lobectomy and patients undergoing thoracotomy (n = 123) lobectomy. A propensity analysis that incorporated preoperative variables, such as age, sex, Charlson comorbidity index, extent of smoking, preoperative pulmonary function, size of the mass, histological type of the tumour and additional lung resection, was performed, and postoperative outcomes were compared.
RESULTS: Matching based on propensity scores produced 91 patients in each group for the analysis of postoperative outcomes. There were only three operative mortalities in the thoracotomy group, and all of these patients died of postoperative pneumonia. The overall incidence of postoperative complications was 32.9% (30 of 91) and 22.0% (20 of 91) in the thoracotomy group and in the VATS group, respectively (P = 0.14). Compared with lobectomy by thoracotomy, VATS lobectomy was associated with a lower incidence of pulmonary complications (1.1 vs 12.1%; P < 0.01), shorter operation time (165 vs 201 min; P < 0.01) and shorter length of stay (6.0 vs 9.0 days; P = 0.04).
CONCLUSIONS: VATS lobectomy is associated with a lower incidence of pulmonary complications compared with lobectomy by thoracotomy in stage I NSCLC patients with COPD. VATS lobectomy may be the preferred strategy for appropriately selected NSCLC patients with COPD.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Pulmonary surgical procedures; Thoracotomy; Video-assisted thoracic surgery

Mesh:

Year:  2013        PMID: 24052605     DOI: 10.1093/ejcts/ezt460

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  19 in total

Review 1.  Video-assisted thoracic surgery and open chest surgery in lung cancer treatment: present and future.

Authors:  Frank Detterbeck; Laureano Molins
Journal:  J Vis Surg       Date:  2016-12-06

2.  VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance).

Authors:  Chukwumere E Nwogu; Jonathan D'Cunha; Herbert Pang; Lin Gu; Xiaofei Wang; William G Richards; Linda J Veit; Todd L Demmy; David J Sugarbaker; Leslie J Kohman; Scott J Swanson
Journal:  Ann Thorac Surg       Date:  2014-12-10       Impact factor: 4.330

3.  The relationship between perioperative administration of inhaled corticosteroid and postoperative respiratory complications after pulmonary resection for non-small-cell lung cancer in patients with chronic obstructive pulmonary disease.

Authors:  Keiji Yamanashi; Satoshi Marumo; Tsuyoshi Shoji; Takamasa Fukui; Ryota Sumitomo; Yosuke Otake; Minoru Sakuramoto; Motonari Fukui; Cheng-Long Huang
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-09-29

4.  Non-intubated thoracoscopic surgery for lung cancer in patients with impaired pulmonary function.

Authors:  Man-Ling Wang; Ming-Hui Hung; Hsao-Hsun Hsu; Kuang-Cheng Chan; Ya-Jung Cheng; Jin-Shing Chen
Journal:  Ann Transl Med       Date:  2019-02

5.  Surgical site infections after lung resection: a prospective study of risk factors in 1,091 consecutive patients.

Authors:  Andrea Imperatori; Elisa Nardecchia; Lorenzo Dominioni; Daniele Sambucci; Sebastiano Spampatti; Giancarlo Feliciotti; Nicola Rotolo
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

6.  Postoperative morphine consumption and anaesthetic management of patients undergoing video-assisted or robotic-assisted lung resection: a prospective, propensity score-matched study.

Authors:  Gary Duclos; Aude Charvet; Noémie Resseguier; Delphine Trousse; Xavier-Benoit D'Journo; Laurent Zieleskiewicz; Pascal-Alexandre Thomas; Marc Leone
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

7.  Algorithm-based troubleshooting to manage bleeding during thoracoscopic anatomic pulmonary resection.

Authors:  Hitoshi Igai; Mitsuhiro Kamiyoshihara; Ryohei Yoshikawa; Fumi Ohsawa; Tomohiro Yazawa; Natsumi Matsuura
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

8.  Effect of comorbidities on long-term outcomes after thoracoscopic surgery for stage I non-small cell lung cancer patients with chronic obstructive pulmonary disease.

Authors:  Takamasa Shibazaki; Makoto Odaka; Yuki Noda; You Tsukamoto; Shohei Mori; Hisatoshi Asano; Makoto Yamashita; Toshiaki Morikawa
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

9.  Short- and long-term outcomes of thoracoscopic pneumonectomy - single center experience.

Authors:  Cezary Piwkowski; Piotr Gabryel; Magdalena Roszak; Bartłomiej Perek; Mariusz Kasprzyk
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2021-02-25       Impact factor: 1.195

10.  Correlation between the presence of circulating tumor cells and the pathologic type and staging of non-small cell lung cancer during the early postoperative period.

Authors:  Zhanqiang Xie; Xiaotian Gao; Keluo Cheng; Lishuang Yu
Journal:  Oncol Lett       Date:  2017-09-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.